Genex has knocked back an offer put forward by a consortium including Atlassian co-founder Scott Farquhar’s investment fund.
The post No deal: Genex share price lifts as $300m takeover bid rejected appeared first on The Motley Fool Australia. –
The renewable energy company’s board said the 23 cents per share offer â representing a 70% premium at the time of its announcement â undervalues the company. Though, it has left the door open for a revised proposal.
The Genex share price is 21.75 cents at the time of writing. That’s 1.16% higher than its previous close.
Let’s take a closer look at the latest news from the ASX-listed company.
Genex share price gains despite rejected bid
The Genex share price is lifting this morning. Its gain comes amid news the company won’t be granting due diligence following a $300 million takeover bid.
The unsolicited bid was put forward by a consortium made up of Atlassian co-founder and co-CEO Scott Farquhar’s Skip Capital and Stonepeak Partners last week.
The company’s board says it believes the bid undervalues the company and, thus, isn’t in shareholders’ best interests.
However, it will allow the consortium access to certain limited due diligence information. It hopes the extra information will help the party put together a revised acquisition proposal.
The Genex board also outlined reasons it believes the company has a bright future, even if it isn’t offered a higher bid.
They included the company’s renewable generation and storage assets, which are worth more than $1 billion.
It also noted Genex’s position as the ASX’s only renewable energy and storage pure play and the company’s 100 megawatts of solar projects â already benefitting from higher pricing.
Finally, it noted the company’s “significant” pipeline of renewable generation and storage projects.
The Genex share price surged 44% when the takeover bid was announced alongside the company’s quarterly report last week.
Today’s gain leaves Genex shares 7.5% higher than they were at the start of 2022. Though, they are 10% lower than this time last year.
The post No deal: Genex share price lifts as $300m takeover bid rejected appeared first on The Motley Fool Australia.
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now
See The 5 Stocks
*Returns as of July 7 2022
setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Atlassian. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.